Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record
Parabilis Medicines grossed $670m from its initial public offering, besting Kailera’s $625m in gross proceeds from an April IPO, in the largest first-time offering ever for a drug developer.
Scrip - June 10, 2026

SonoThera Raises $125m To Advance Next-Gen DMD Gene Therapy
With two proprietary platforms for ultrasound-driven delivery and targeting as well as novel therapeutic payloads, the biotech believes it can improve upon viral vector gene therapies.
Scrip - June 10, 2026

J&J Opts Not To Follow The Oncology Crowd
J&J exec Mark Wildgust sat down with Scrip at ASCO to discuss the drugmaker’s swing-for-the-fences approach to drug development.
Scrip - June 10, 2026

ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations
AstraZeneca is moving its GLP-1 agonist contender, elecoglipron, into Phase III trials that include cardiovascular drugs combinations, in the hope that it can unlock a huge global market.
Scrip - June 10, 2026

Insights from industry leaders on China’s rise as a global powerhouse in drug innovation
Article: From China’s biotech hubs to the world
Scrip - June 10, 2026

Opportunities and Best Practices in Early Phase Research
Whitepaper: Early Phase Challenges for Biotechs
Scrip - June 10, 2026

Sanofi Stops Phase III MOBILIZE Study As It Reviews Riliprubart’s CIDP Program
While the company continues to evaluate the future of the VITALIZE trial, the outcome clouds the outlook for one of the more advanced complement-targeting candidates in the indication.
Scrip - June 10, 2026

Improved access, broader participation, and faster enrollment through community-based trials
Broadening reach through patient optionality and community-based trials
Scrip - June 10, 2026

WuXi AppTec, Novogene Added To Pentagon List Of ‘Chinese Military Companies’
The Pentagon's list of Chinese companies owned and influenced by the military or government is expected to help shape BIOSECURE Act designations of "biotechnology companies of concern" due by December.
Scrip - June 10, 2026

Endogene.bio CEO On A Menstrual-Blood Test For Endometriosis
A methylation sequencing assay on uncultured menstrual stem cells hit 79% sensitivity and 83% specificity across two independent sites — early data endogene.bio CEO María Teresa Pérez Zaballos frames as a route to molecular stratification, not just diagnosis.
Medtech Insight - June 11, 2026

New York Setting Limits For Mercury In Cosmetics, Personal Care
New York's DEC is moving to restrict mercury in cosmetics — particularly skin-lightening products — while also clarifying how companies must demonstrate compliance with the state's existing 1,4-dioxane limits.
HBW Insight - June 11, 2026

Lupin’s COPD Inhaler Spreads Further In Europe
Lupin’s Spanish Luforbec launch extends its respiratory footprint across major European markets, as the company builds inhalation into a core complex-products growth platform.
Generics Bulletin - June 10, 2026

Kashiv Biosciences Files Xolair Biosimilar In Canada
With a $135m Canadian market opportunity and Celltrion as the only approved rival, Kashiv's filing targets a competitive but not yet crowded omalizumab biosimilar landscape.
Generics Bulletin - June 10, 2026

Hetero Deal Gives Richter Another Route Into Semaglutide
Richter has added Hetero as a global semaglutide partner, advancing its GLP-1 strategy beyond Adalvo as filings are prepared for 2027.
Generics Bulletin - June 10, 2026

Accord Downs Purdue On US OxyContin Appeal
Accord Healthcare has prevailed at the US Court of Appeals for the Federal Circuit in a patent dispute over Purdue’s reformulated OxyContin, with the appeals court upholding a ruling that a key tamper-resistant oxycodone claim is invalid for obviousness.
Generics Bulletin - June 10, 2026

Legal Issues Loom Large At Medicines For Europe Conferences
There was no shortage of major legal and legislative topics to dissect at Medicines for Europe’s legal affairs conference in Athens this week, with debate and discussion continuing into the association’s annual conference that begins today.
Generics Bulletin - June 10, 2026

US Biotech, Policymakers Should Focus On Competing More Effectively With China, EY Says
In its latest Biotech Beyond Borders report, EY analysts argue that the US biotech sector should focus on competing better with China, rather than attempting to constrain it.
In Vivo - June 10, 2026

Leaders At The Frontier: Conversations From SynBioBeta 2026
At SynBioBeta 2026, In Vivo spoke with founders, investors and platform builders at the intersection of synthetic biology and biopharma. Their conversations reveal a field maturing fast – but with clear-eyed leaders who know exactly where the hype ends and the hard work begins.
In Vivo - June 10, 2026